Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects

Inclusion Criteria: * Willingness and are able to provide a written informed consent to participate in the study. * Healthy adult male subjects aged between 18 and 45 (both inclusive) years old * BMI between 19 and 23 kg/m2. Overweight (BMI between 23 and 25kg/m2) and/or obese (BMI between 25 and 35 kg/m2) but otherwise healthy subjects in PartB . * Healthy as determined by the investigator * Smoking less than 10 cigarettes per day and able to refrain from smoking during confinement. * Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, "power drinks") and grapefruit juice to admission. Exclusion Criteria: * Employees of the sponsor or clinical sites. * Female subjects. * No past or current serious diseases of any organ will be allowed. Exceptions may be non-malignant skin diseases, childhood asthma and other conditions as per the Investigator's discretion and discussed with the Sponsor a priori. History of significant gastrointestinal disease or other significant diseases including cardiac, renal or liver impairment. * History of sleep apnea, irregular sleep/wake cycle or working in night shifts. * Acute disease state * History of hypo/hyperthyroidism or repeated abnormal TSH values at screening or obesity of endocrine origin. * History of alcoholism for more than 2 years * Positive serology for human immunodeficiency virus (HIV-1/2) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies. * Positive findings in urine drug screen / alcohol breath test. * Participation in another clinical trial within 90 days of the first drug administration. * Intake of more than 8-10 cups of coffee and/or tea per day and consumption of methyl xanthine-containing beverages (tea, coffee, cola drinks, chocolate) within 48 hours prior to study. * Donation of blood (i.e. 350 ml) within 90 days before Day -1 of the first treatment period.